Q2 2025 Lucid Diagnostics Inc Earnings Call Transcript
Key Points
- Lucid Diagnostics Inc (LUCD) reported a 40% increase in revenue from the first quarter, reaching $1,200,000, which matches their previous quarterly high.
- The company successfully partnered with HOGUE, a large health system in Orange County, California, to launch a comprehensive EsoGuard Esophageal Precancer Testing Program.
- Lucid Diagnostics Inc (LUCD) strengthened its balance sheet with an underwritten public offering, netting $16,100,000 in proceeds, bringing their cash reserves to $30,000,000.
- The company has a robust pipeline for cash-paying contracted programs targeting concierge medicine practices and self-insured entities, showing steady progress.
- Lucid Diagnostics Inc (LUCD) is optimistic about securing Medicare coverage, with a Multi X Contractor Advisory Committee meeting scheduled, indicating progress towards a positive outcome.
- The company is still in the early stages of the reimbursement process, with revenue recognition dependent on the probability of collection, leading to delays in recognizing revenue.
- Lucid Diagnostics Inc (LUCD) has a quarterly burn rate of $10,300,000, which could be a concern if revenue growth does not accelerate.
- The company faces challenges in securing broad commercial coverage, with some plans potentially waiting for Medicare approval before committing.
- There is uncertainty regarding the timeline for finalizing Medicare coverage, with potential delays pushing the final decision into 2026.
- A significant portion of claims submitted are still pending or denied, with issues such as being deemed not medically necessary or requiring additional medical records.
Good morning and welcome to the Lucid Diagnostic 2nd quarter 2025 business update conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator.
Please note that this event is being recorded. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics, senior director of Investor Relations. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for participating in todayâs business update call. Joining me today on the call are Doctor. Lishan Aklod, Chairman and CEO of Lucid Diagnostics along with Dennis McGrath, Chief Financial Officer. The press release announcing our business update and financial results is available on Lucidâs website.
Please take a moment to read the disclaimers about forward looking statements in the press release. The business
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
